Would you prescribe an aromatase inhibitor prophylactically for a post-menopausal woman with a deleterious BRCA2 mutation and a history of DCIS who declines prophylactic mastectomy?
Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-menopausal women and consider an AI
Answer from: Medical Oncologist at Academic Institution
The IBIS II trial (Lancet Onc Forbes et al 2016) established anastrazole was non inferior but not superior in preventing recurrences after DCIS. The MAP3 trial (Goss NEJM) demonstrated efficacy of extemestane vs tamoxifen in the chemoprevention of a first breast cancer in higher risk postmenopausal ...
Sign in or Register to read more